The Trump-Vance administration is navigating significant calls to strengthen drug policies amidst growing concerns about the normalisation of addiction. Public sentiment appears to shift, with seven of the last ten US ballot measures to legalise marijuana rejected. Experts underline the risks of modern, highly potent cannabis, pointing to evidence that secondhand marijuana smoke may pose greater health risks than tobacco smoke. The rise of ‘cannabis cafes’, such as those recently legalised in California, has prompted appeals for stricter national regulations to mirror bans on indoor cigarette smoking.

Health advocates emphasise the need for greater transparency within the medical marijuana industry. Proposals include a public registry to monitor overprescribing patterns, financial links to the cannabis sector, and regional usage trends. This initiative is likened to actions that helped address unethical practices during the opioid crisis.

Debate continues over the potential rescheduling of marijuana to a lower drug classification. Critics argue that it does not meet existing criteria for reclassification and warn that such a move could expand corporate influence while increasing drug accessibility, with three in ten marijuana users reportedly developing dependency.

Federal enforcement is highlighted as an essential component in addressing the issue. Recommendations include measures to prevent marijuana sales to minors, deter drugged driving, and eliminate illegal cannabis farming operations tied to environmental harm and criminal activities. Advocates are also calling for an updated national anti-drug media campaign, leveraging social media and modern communication channels to educate young people on the risks of drug use.

With addiction and its consequences placing a strain on communities, efforts to focus on prevention, accountability, and enforcement are seen as critical to fostering public health and safety.

Source: Newsweek